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Summary 
The B7 family consists of structurally related, cell-surface protein ligands, which bind to receptors
on lymphocytes that regulate immune responses. Activation of T and B lymphocytes is initiated by
engagement of cell-surface, antigen-specific T-cell receptors or B-cell receptors, but additional
signals delivered simultaneously by B7 ligands determine the ultimate immune response. These
‘costimulatory’ or ‘coinhibitory’ signals are delivered by B7 ligands through the CD28 family of
receptors on lymphocytes. Interaction of B7-family members with costimulatory receptors
augments immune responses, and interaction with coinhibitory receptors attenuates immune
responses. There are currently seven known members of the family: B7.1 (CD80), B7.2 (CD86),
inducible costimulator ligand (ICOS-L), programmed death-1 ligand (PD-L1), programmed death-
2 ligand (PD-L2), B7-H3, and B7-H4. Members of the family have been characterized
predominantly in humans and mice, but some members are also found in birds. They share 20-
40% amino-acid identity and are structurally related, with the extracellular domain containing
tandem domains related to variable and constant immunoglobulin domains. B7 ligands are
expressed in lymphoid and non-lymphoid tissues. The importance of the family in regulating
immune responses is shown by the development of immunodeficiency and autoimmune diseases
in mice with mutations in B7-family genes. Manipulation of the signals delivered by B7 ligands has
shown potential in the treatment of autoimmunity, inflammatory diseases and cancer. 
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Gene organization and evolutionary history
The seven known members of the B7 family - B7.1, B7.2,
ICOS-L, PD-L1, PD-L2, B7-H3, and B7-H4 - are all trans-
membrane or glycosylphosphatidylinositol (GPI)-linked
proteins characterized by extracellular IgV and IgC domains
related to the variable and constant domains of
immunoglobulins (Table 1; see [1-3] for detailed reviews on
the family). The IgV and IgC domains of B7-family members
are each encoded by single exons, with additional exons
encoding leader sequences, transmembrane and cytoplasmic
domains. B7-H3 is unique in that the major human form
contains two extracellular tandem IgV-IgC domains (Table
1) [4]. Differentially spliced forms have been identified for
B7.1, B7.2, ICOS-L, B7-H3, and PD-L2 [4-9], although the
functional significance of these splice forms is unclear. The
cytoplasmic domains are short, ranging in length from 19 to
62 amino-acid residues (see Additional data file 1), and can
be encoded by multiple exons. A function for the intracellu-
lar domains has not been established, although they all
contain serine and threonine residues that could potentially
serve as phosphorylation sites in signaling pathways. Recent
evidence suggests that B7-family members can signal into
the cell on which they are expressed (see below). One
member, B7-H4, is GPI-linked to the cell surface [10,11],
whereas all others have transmembrane domains. 
The genes for B7.1 and B7.2 are closely linked, as are the
genes for PD-L1 and PD-L2, whereas the genes for ICOS-L,B7-H3 and B7-H4 are unlinked (Table 2). Orthologs of B7.1
and B7.2 have been identified in diverse mammalian species,
but genes for other family members remain to be defined in
most species beyond primates and rodents (Table 3). Inter-
estingly, genes annotated as B7.1, B7.2, ICOS-L and B7-H4
orthologs have been described in the chicken, Gallus gallus,
indicating that the family is conserved in birds (Figure 1; see
also Table 3). A BLAST search of the NCBI Fugu rubripes
(pufferfish) sequence database suggests that there may also
be B7-like proteins in bony fish (data not shown), and CD28-
like and CTLA-4 like molecules have been identified in trout
(GenBank accession numbers AAW78853 and AAW78854).
The CD28-receptor family is also conserved across mam-
malian species, and chicken orthologs have been described
[12], suggesting that these receptor-ligand interactions are
critical in the regulation of immune responses in mammals,
birds and probably also fish.
Characteristic structural features
Members of the B7 family (Table 1) are predicted to form
homodimers at the cell surface, as has been shown for B7.1,
although recent data indicate that B7.2 is likely to be a
monomer [13]. B7.1 and B7.2 share only about 25% amino-
acid identity, yet each interacts with both CD28 and CTLA-4
receptors. Crystal structures have been solved for human
B7.1 [14] and human B7.2 [13], both alone and complexed
with the CTLA-4 receptor [15,16]. The structures of human
B7.1 and B7.2 extracellular domains reveal typical IgV-like
and IgC-like domains. Immunoglobulin-superfamily
domains are typically about 100 amino acids in length and
form a structure characterized by two anti-parallel  sheets,
with each sheet composed of three to five anti-parallel
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Table 2
Chromosomal locations of B7-family genes
Chromosomal location
Gene Human Mouse
B7.1 3q21 16
B7.2 3q21 16
ICOS-L 21q22.3 10
PD-L1 9p24 19
PD-L2 9p24.2 19
B7-H3 15q23-q24 9
B7-H4 1p13.1-p12 3
See the database entries for the accession numbers given in Table 3 for
links to genetic mapping data.
Table 1
Structures, expression patterns and receptors of B7 ligands
Ligand name  mRNA expression Function of
(alternative  Protein expression  in non-lymphoid  ligand-receptor 
names) Structure pattern in lymphoid cells* tissues or cells  Receptor interaction
B7.1 (CD80) Induced in T, B, DCs,  Not detected CD28 Costimulation
and monocytes CTLA-4 (CD152) Coinhibition
B7.2 (CD86) Constitutive and upregulated  Not detected CD28 Costimulation
upon activation in B, DCs,  CTLA-4 (CD152)  Coinhibition
and monocytes; induced in T
ICOS-L (GL-50,   Constitutive in B, DCs,  Lung, liver, kidney, and  ICOS Costimulation
B7h, B7RP-1,  macrophages, and a subset  testes
B7H-2) of T
PD-L1 (B7-H1) Constitutive and upregulated  Placenta, heart, pancreas,  PD-1 Coinhibition
upon activation in B, DCs,  lung, liver, and tumor cells  Unknown? Costimulation
and monocytes; induced in T (carcinomas and melanomas)
PD-L2 (B7-DC) Induced in DCs and  Heart, placenta, lung, liver PD-1 Coinhibition
monocytes keratinocytes, and epithelial  Unknown? Costimulation
cells
B7-H4  Induced in T, B, NK, DCs,  Placenta, uterus, testis, kidney,  Unknown Coinhibition
(B7x, B7S1) and monocytes lung, heart, and brain
B7-H3 Mouse Induced in T, B, DCs, and Heart, kidney, testes, lung,   Unknown Costimulation
monocytes liver, pancreas, prostate,  Unknown Coinhibition
colon, and osteoblasts
Human 
*Abbreviations: B, B cells; DCs, dendritic cells; NK, natural killer cells; T, T cells; Unknown?, postulated receptor. 
IgC IgV
IgC IgV
IgC IgV
IgC IgV
IgC IgV GPI
IgC IgV
IgV IgC IgV IgC
IgC IgVstrands [17-19]. The distinction between IgV and IgC
domains is based on their structures, with IgV domains con-
taining nine anti-parallel strands and IgC domains contain-
ing seven anti-parallel strands. Immunoglobulin-superfamily
domains are found in many proteins and often serve as
protein-protein interaction domains, as is frequently seen
for cell-surface proteins in the immune system. For B7.1 and
B7.2, the amino-terminal IgV domain is the receptor-
binding domain. Interestingly, the amino-acid residues
within B7.1 and B7.2 that bind to CTLA-4 are not highly con-
served. A comparison of the two structures reveals, however,
that the front faces of B7.1 and B7.2 each have shallow cavi-
ties that allow the highly conserved MYPPPY motif (in the
single letter amino-acid code) in the CD28 and CTLA-4
receptors to fit and bind [13] (see Figure 2). 
B7.1 and B7.2 have non-equivalent roles in immune modula-
tion, in part because of their different interactions with
CD28 and CTLA-4. The B7.1-CTLA-4 interaction is of higher
affinity than the B7.2-CTLA-4 interaction, whereas CD28 is
predicted to bind B7.2 more effectively than B7.1 [20]. Co-
crystals of B7.1 with CTLA-4 reveal that B7.1 homodimers
have CTLA-4-binding sites that are distal from the B7 dimer
interface, allowing formation of a cross-linked B7-CTLA-4
lattice [15] (see Figure 3). In contrast, the data support a
monovalent interaction between B7.2 and CD28 [20]. These
models predict that the B7.1-CTLA-4 and B7.2-CD28 inter-
actions will be of the greatest functional significance (see
[21,22] for further discussion). A crystal structure of the
CD28 extracellular domain has recently been reported and
shows similarities with that of CTLA-4 [23]. Crystal struc-
tures for other B7-family members have not yet been
reported. Binding affinities of ICOS-L to its receptor have
been reported to be similar to those of CD28-B7.1 interac-
tions [24]. PD-L1 and PD-L2 both have IgV-IgC extracellular
domains, and both bind the same PD-1 receptor, although
PD-L2 has been reported to bind PD-1 with an affinity 2-6
times higher than the affinity with which PD-L1 binds PD-1
[25]. The crystal structure of the extracellular domain of
PD-1 has recently been reported [26].
Localization and function
Expression of B7 ligands
Expression of B7.1, B7.2 and PD-L2 is restricted to lym-
phoid cells, whereas ICOS-L, PD-L1, B7-H3 and B7-H4 are
also expressed on non-lymphoid cells, suggesting that they
have distinct roles in immune function. PD-L1, B7-H3 and
B7-H4 expression has also been reported in tumor-cell lines
(Table 1) [27]. All B7 ligands are expressed by antigen-
presenting cells, including dendritic cells, macrophages and
B cells, all of which function in the initiation and amplifica-
tion of immune responses (Table 1). Low levels of B7.2
protein expression are detected on resting B cells, dendritic
cells and macrophages; activation results in enhanced B7.2
expression and de novo expression of B7.1. ICOS-L is con-
stitutively expressed in human monocytes and dendritic
cells, and its expression is upregulated in monocytes by
interferon- [3,28]. 
Expression of PD-L1 and PD-L2, the independent ligands for
the PD-1 receptor, is differentially regulated by cytokines:
interleukins IL-4 and IL-13 upregulate PD-L2 [29,30],
whereas inflammatory cytokines, primarily interferon-,
modulate PD-L1 expression [3,31]. PD-L2 expression is
restricted to dendritic cells and macrophages, whereas PD-
L1 is also expressed by B and T cells and non-lymphoid cells.
The distinct tissue expression and cytokine modulation of
PD-L1 and PD-L2 suggest non-overlapping roles during an
immune response, with PD-L1 predominating in the periph-
eral tissues and PD-L2 in lymphoid organs.
B7-H3 and B7-H4 are constitutively expressed in murine,
but not human, antigen-presenting cells [4,10,11,32,33].
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Table 3
Accession numbers for the amino-acid sequences of B7-family proteins from selected species
Protein Human Mouse Dog Cat Cow Rabbit Sheep Pig Chicken
B7.1 NP_005182 NP_033985 NP_001003147 BAB11687 CAA71081 I46690 AAR27296 NP_999252 NP_990415
B7.2 NP_787058 NP_062261 NP_001003146 BAB11688 CAC13140 I46691 AAR89183 NP_999387 XP_425516
ICOS-L NP_056074 NP_056605 N/A N/A N/A N/A N/A N/A XP_413702
PD-L1 NP_054862 NP_068693 N/A N/A N/A N/A N/A N/A N/A
PD-L2 NP_079515 NP_067371 N/A N/A N/A N/A N/A N/A N/A
B7-H3 NP_079516VC, NP_598744 N/A N/A N/A N/A N/A N/A N/A
CAE47548VCVC
B7-H4 NP_078902 NP_848709 N/A N/A N/A N/A N/A N/A XP_416546,  
XP_416760
Data obtained from the NCBI Protein Refseq Database [48]. N/A: not available. See the database entries under these accession numbers for well-
annotated sequences and references to many of the original publications defining the genes.B7-H3 transcripts or protein are not detected in resting
human peripheral blood lymphocytes [10,11,34,35], but in
murine dendritic cells B7-H3 expression is upregulated by
interferon- and downregulated by IL-4 [36], suggesting
that B7-H3 may regulate immune responses mediated by T
helper type 1 inflammatory T cells. The low level of expres-
sion of B7-H4 protein in tissues suggests that it may be
regulated post-transcriptionally [10,11,34,35]. Inflamma-
tory stimuli and activation downregulate B7-H4 cell-
surface expression in murine B cells [10]; the mechanism
by which this occurs has yet to be clarified. Receptors for
B7-H3 and B7-H4 have not been identified, although
expression of these ligands modulates immune responses
[4,10,11,32,33,35].  
Multiple interactions and multiple functional
outcomes
B7 ligands participate in immune responses by providing
costimulatory or coinhibitory signals upon binding their
receptor. Costimulatory signals are defined as those that act
in conjunction with antigen-receptor signals, leading to pro-
ductive cell activation, growth-factor production, cell expan-
sion and survival (Figure 4a). In contrast, coinhibitory
signals attenuate antigen-receptor signals, resulting in
decreased cell activation, inhibition of growth-factor produc-
tion, inhibition of progression of the cell cycle and, in some
cases, increased cell death (Figure 4b). The B7 ligands B7.1
and B7.2 and their receptors CD28 and CTLA-4 exemplify a
costimulatory-coinhibitory system that acts to regulate
immune responses. Mice deficient in B7.1 and B7.2 have pro-
found deficits in both humoral immune responses (antibody
production) and cellular immune responses [37]. Similarly,
mice deficient in the CD28 receptor are unable to mount
effective immune responses to foreign antigens, infectious
pathogens or foreign tissue grafts (allografts) [38]. Thus, the
interaction of B7.1 and B7.2 with the CD28 receptor results
in costimulatory signals leading to the productive activation,
expansion, differentiation and survival of T cells, with result-
ing effective antibody-mediated and cellular immune
responses (Table 1). This productive immune response is
kept in balance by the attenuation signal delivered through
B7-ligand-CTLA-4 receptor interactions. Thus, in CTLA-4-
deficient mice, a severe autoimmune phenotype develops,
with death occurring 3-4 weeks after birth as a result of mul-
tiorgan destruction [39,40]. Interestingly, the absence of
B7.1 and B7.2 signals ablates the autoimmune phenotype in
triple-mutant mice deficient in B7.1, B7.2 and CTLA-4 [41].
These findings demonstrate that B7-CTLA-4 interactions
223.4 Genome Biology 2005, Volume 6, Issue 6, Article 223 Collins et al. http://genomebiology.com/2005/6/6/223
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Figure 2
Details of the interaction between human CTLA-4 and B7.1. (a) Overview
of the interaction. The structure of soluble CTLA-4 monomer (left)
interacting with soluble B7.1 monomer (right) is shown as a ribbon
diagram, with the molecular surface of the soluble B7.1 monomer
overlaid in white. (b) Close-up view of the interaction. The MYPPPY
sequence from CTLA-4 (in ball and stick representation) interacts with
residues forming a shallow depression in the IgV domain of B7.1. Three
out of the five hydrogen bonds formed across the  sheets of the
interacting domains are depicted by dashed lines. Reproduced with
permission from [15].
(a) (b)
Figure 1
A phylogenetic tree of the B7 family. Sequence alignments were
performed using ClustalW implemented in the AlignX module of
Vector NTI version 9.1; alignments were imported into Mega 2.1 [47]
and a phylogenetic tree was created using the neighbor-joining method
(the setting for gaps and missing data was pairwise deletion; the
distance method used was number of differences). Numbers at selected
nodes indicate the percentage frequencies of branch association on the
basis of 1,000 bootstrap repetitions. The scale bar indicates number of
residue changes. 
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68counteract B7-CD28 interactions, resulting in precise regu-
lation of T-cell receptor and CD28 signals, interleukin-2 pro-
duction and cell-cycle progression. 
Recently, it has been reported that engagement of B7.1 and
B7.2 leads to ‘reverse signaling’ through B7.1 and B7.2
[42,43]. In dendritic cells, engagement of B7.1 or B7.2 with
CTLA4.Ig, a soluble CTLA-4-immunoglobulin chimeric
protein, leads to production of indoleamine 2,3-dioxygenase
(IDO) and decreased tryptophan levels, resulting in inhibi-
tion of T-cell proliferation and cell death [42] (Figure 4b). In
contrast, engagement of B7.1 and B7.2 with CD28.Ig results
in induction of IL-6 production [43] (Figure 4a). Interest-
ingly, this bidirectional signaling could explain the increased
survival of cardiac allografts in CD28-/-CTLA-/- mice treated
with CTLA4.Ig [44]. Further elucidation of reverse B7 signal-
ing is necessary if we are to understand how this contributes
to the overall outcome of receptor-ligand interactions. 
In summary, B7.1 and B7.2 can either costimulate or coin-
hibit immune responses through interaction with their
receptors, providing temporal and spatial control of immune
responses. Similar costimulatory and coinhibitory para-
digms apply to other members of the B7 family, as outlined
in Table 1, although details of these pathways are still emerg-
ing. Conservation of the B7 family of ligands in species with
cellular immune systems underscores the functional impor-
tance of B7 ligands in regulating signals delivered by
antigen-specific receptors on immune cells. 
Frontiers
The B7 family has a critical role in controlling immune
responses, as was initially shown for B7.1 and B7.2 and
extended by the recent identification and characterization of
new B7-family members. Inflammatory stimuli modulate
expression of B7 ligands, resulting in the delivery of activat-
ing and attenuating signals that determine the nature and
extent of subsequent immune responses. Crystal structures,
affinity measurements and biological assays have demon-
strated how B7.1 and B7.2 deliver specific signals to immune
cells resulting in precise regulation of immune function.
This detailed level of knowledge is still to be obtained for
additional members of the family. The receptors for B7-H3
and B7-H4 remain to be identified, and the available data
suggest that there may be additional receptors for PD-L1
and PD-L2. Further clarification is needed before we under-
stand how signals delivered by B7-family ligands are inte-
grated spatially and temporally with those derived from
antigen-specific receptors. Therapeutic manipulation of B7
signaling has shown clinical promise [45,46], underscoring
the key role that B7-family ligands play in regulating
immune responses. 
Additional data files
A sequence alignment for the proteins that were used to
make the phylogenetic tree in Figure 1 is available in Addi-
tional data file 1. This alignment was made using Pileup and
the Blosum62 scoring matrix.
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Figure 3 
Proposed periodic arrangement of CTLA-4 molecules on the surface of a T cell bound to B7-1 molecules on the surface of an antigen-presenting cell. This
model is based on the molecular association of CTLA-4 and B7.1 observed in the crystal lattice structure. The proposed lattice structure would enhance
the stability of CTLA-4 and B7.1 interactions on the cell surface. C, carboxyl terminus; N, amino terminus. Reproduced with permission from [15]. 
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Figure 4
Costimulation and coinhibition. The binding of CD28 or CTLA-4 receptors
on T cells by B7.1 and B7.2 ligands on antigen-presenting cells (APCs) can
lead to either costimulation or coinhibition depending upon the precise
expression patterns of the receptors and ligands and on the state of
activation of the two cells. (a) CD28 is expressed on resting T cells and can
be engaged by either B7.1 or B7.2 on APCs. Current models favor
preferential engagement by B7.2, leading to activation of resting T cells. This
costimulation leads in the T cell to increased production of growth factors,
such as interleukin-2 (IL-2) and increased cell-survival signals, such as Bcl-X.
Reverse signaling by CD28 engagement of B7.1 (not shown) or B7.2 ligands
resulting in production of interleukin-6 (IL-6) by the APC has also been
described. (b) CD28 and CTLA-4 are both expressed on activated T cells,
and both receptors on T cells can be engaged by B7.1 or B7.2 on APCs.
Current models favor preferential engagement of CTLA-4 by B7.1, resulting
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